Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
JournalFrontiers in immunology
MetadataShow full item record
AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for hematologic malignancies, and other hematologic and immunologic diseases. Donor-derived immune cells identify and attack cancer cells in the patient producing a unique graft-vs.-tumor (GVT) effect. This beneficial response renders allo-HCT one of the most effective forms of tumor immunotherapy. However, alloreactive donor T cells can damage normal host cells thereby causing graft-vs.-host disease (GVHD), which results in substantial morbidity and mortality. To date, GVHD remains as the major obstacle for more successful application of allo-HCT. Of special significance in this context are a number of cytotoxic pathways that are involved in GVHD and GVT response as well as donor cell engraftment. In this review, we summarize progress in the investigation of these cytotoxic pathways, including Fas/Fas ligand (FasL), perforin/granzyme, and cytokine pathways. Many studies have delineated their distinct operating mechanisms and how they are involved in the complex cellular interactions amongst donor, host, tumor, and infectious pathogens. Driven by progressing elucidation of their contributions in immune reconstitution and regulation, various interventional strategies targeting these pathways have entered translational stages with aims to improve the effectiveness of allo-HCT.
Keywordallogeneic hematopoietic cell transplantation (allo-HCT)
Fas/Fas ligand (FasL) system
Graft vs Host Disease
Graft vs Tumor Effect
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85059828139&doi=10.3389%2ffimmu.2018.02979&partnerID=40&md5=31a0d68ed1e84b8ef27e95359da7cc16; http://hdl.handle.net/10713/8822
- Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.
- Authors: Du W, Mohammadpour H, O'Neill RE, Kumar S, Chen C, Qiu M, Mei L, Qiu J, McCarthy PL, Lee KP, Cao X
- Issue date: 2018
- The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
- Authors: Wang H, Yang YG
- Issue date: 2014 Mar
- Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
- Authors: Rezvani AR, Storb RF
- Issue date: 2008 May
- Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
- Authors: Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR
- Issue date: 2001 May 1